ASMB — Assembly Biosciences Share News
0.000.00%
Last trade - 00:00- $403.95m
- $83.59m
- $72.30m
U.S. STOCKS ON THE MOVE-Rivian, One Medical, Evofem Biosciences
U.S. STOCKS ON THE MOVE-Philip Morris, AT&T, Olema Pharmaceuticals
Assembly Biosciences to cut staff, shares up
Brief: Assembly Biosciences Says Plan Includes A Reduction Of Workforce By 30 Employees
Brief: Assembly Biosciences Announces Program Reprioritization And Organizational Update
Brief: Assembly Biosciences Presents New Data Highlighting Clinical Progress Of Core Inhibitor Programs
Brief: Assembly Biosciences Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor Abi-H3733
Brief: Assembly Biosciences - Effective May 20, Because Of Clinical Hold On Ati-2173, Co Terminated Clinical Trial Collaboration Agreement With Antios
Assembly Biosciences Inc expected to post a loss of 47 cents a share - Earnings Preview
Jefferies cuts Assembly Biosciences' PT on low expectations for hepatitis D pill
U.S. RESEARCH ROUNDUP- Blend Labs, Unifirst, Vertiv Holdings
Brief: Assembly Biosciences Reports Fourth Quarter And Year End 2021 Financial Results And Recent Highlights
Assembly Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Assembly Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Assembly Biosciences Presents Data Of HBV Core Inhibitor Portfolio At Liver Meeting
Assembly Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Assembly Biosciences Reports Q3 Loss Per Share Of $0.41
Assembly Biosciences Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Antios, Assembly Biosciences To Collaborate To Test Combination Of ATI-2173 And Vebicorvir In Patients With Chronic Hepatitis B Virus Infection